Related Experiment Videos
Potential indications for octreotide in endocrinology
1Department of Medicine, Schlosspark-Klinik, Teaching Hospital of the Free University, Berlin, Germany.
Metabolism: Clinical and Experimental
|September 1, 1992
Summary
Sandostatin effectively treats acromegaly and certain tumors. Further research is needed for other conditions like Graves' ophthalmopathy, where patient subgroups may benefit and can be identified using Sandostatin scintigraphy.
Area of Science:
- Endocrinology
- Medical Therapeutics
Background:
- Sandostatin is a recognized treatment for acromegaly, TSH-producing pituitary tumors, and gastroenteropancreatic neuroendocrine tumors.
- Its efficacy is also explored for various other endocrine disorders and syndromes.
Purpose of the Study:
- To review the established and potential therapeutic applications of Sandostatin.
- To highlight the role of Sandostatin scintigraphy in identifying patient subgroups who may respond to treatment.
Main Methods:
- Review of established Sandostatin treatments.
- Discussion of potential indications and supporting evidence.
- Emphasis on diagnostic utility of Sandostatin scintigraphy.
Main Results:
- Sandostatin is unequivocally effective in ectopic growth hormone-releasing hormone (GHRH) syndrome.
- Selected cases of ectopic corticotropin syndrome show marked clinical improvement with Sandostatin.
- Subgroup identification via Sandostatin scintigraphy is crucial for predicting treatment response in various conditions, including Graves' ophthalmopathy.
Conclusions:
- Sandostatin has established roles and promising potential in managing diverse endocrine conditions.
- Sandostatin scintigraphy aids in patient selection for therapy, particularly in Graves' ophthalmopathy.
- Larger clinical studies are required to confirm efficacy for all potential indications.